TWI324604B
(en)
|
2003-06-18 |
2010-05-11 |
Novartis Ag |
New use of staurosporine derivatives
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
CA2533861A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Novartis Ag |
Combinations comprising staurosporines
|
US20080221080A1
(en)
|
2003-08-25 |
2008-09-11 |
James Douglas Griffin |
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
|
AU2004291147A1
(en)
|
2003-11-13 |
2005-06-02 |
Ambit Biosciences Corporation |
Urea derivatives as kinase modulators
|
WO2005053704A1
(en)
*
|
2003-12-01 |
2005-06-16 |
Novartis Ag |
Method for predicting drug responsiveness in myeloid neoplasms
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
EP1778224B1
(en)
*
|
2004-07-19 |
2014-03-26 |
The Johns-Hopkins University |
Flt3 inhibitors for immune suppression
|
GB0419159D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
RU2007123675A
(en)
*
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
JAK INHIBITOR COMBINATIONS
|
GB0426821D0
(en)
*
|
2004-12-07 |
2005-01-12 |
Novartis Ag |
Organic compounds
|
RS54876B1
(en)
|
2005-05-10 |
2016-10-31 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
BRPI0613868A2
(en)
*
|
2005-07-20 |
2011-02-15 |
Novartis Ag |
organic compounds
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
CA2626623C
(en)
|
2005-10-18 |
2016-08-30 |
Janssen Pharmaceutica N.V. |
Method of inhibiting flt3 kinase
|
GB0522932D0
(en)
*
|
2005-11-10 |
2005-12-21 |
Univ Southampton |
PKC412 in treatment of atypical chronic myeloid leukemia
|
CA2629478C
(en)
*
|
2005-11-14 |
2013-10-15 |
Universitat Zurich |
Staurosporine derivatives for use in alveolar rhabdomyosarcoma
|
MY159449A
(en)
|
2005-12-13 |
2017-01-13 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
EP2016070B1
(en)
|
2006-04-20 |
2016-01-13 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
KR101367645B1
(en)
|
2006-04-20 |
2014-02-27 |
얀센 파마슈티카 엔.브이. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
GB0612542D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Novartis Ag |
Combinations comprising staurosporines
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
TR201903488T4
(en)
|
2007-06-13 |
2019-04-22 |
Incyte Holdings Corp |
Use of Janus kinase inhibitor (r) -3- (4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) -3-cyclopentylpropannitrile salts.
|
CL2008001709A1
(en)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
|
JO3240B1
(en)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
Inhibitors of c-fms Kinase
|
CN101910152B
(en)
|
2007-11-16 |
2014-08-06 |
因塞特公司 |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
UA101493C2
(en)
|
2008-03-11 |
2013-04-10 |
Инсайт Корпорейшн |
Azetidine and cyclobutane derivatives as jak inhibitors
|
WO2009132202A2
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
MY171866A
(en)
|
2008-07-08 |
2019-11-05 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
CL2009001884A1
(en)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
AR076920A1
(en)
|
2009-05-22 |
2011-07-20 |
Incyte Corp |
3- (4- (7H-PIRROLO (2,3-D) PIRIMIDIN-4-IL) -1H-PIRAZOL-1-IL) OCTANO-O HEPTANO - NITRILE AS JAK INHIBITORS
|
WO2010135650A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
AR077280A1
(en)
|
2009-06-29 |
2011-08-17 |
Incyte Corp |
PYRIMIDINONES AS PI3K INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
|
AR078012A1
(en)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
|
WO2011044481A1
(en)
|
2009-10-09 |
2011-04-14 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
EP2327706A1
(en)
*
|
2009-11-30 |
2011-06-01 |
Novartis AG |
Polymorphous forms III and IV of N-benzoyl-staurosporine
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
AR079529A1
(en)
|
2009-12-18 |
2012-02-01 |
Incyte Corp |
ARILO AND HETEROARILO DERIVATIVES REPLACED AND FOUNDED AS INHIBITORS OF THE PI3K
|
WO2011083124A1
(en)
|
2010-01-05 |
2011-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
CA2786800C
(en)
|
2010-01-12 |
2018-02-27 |
Ab Science |
Thiazole and oxazole kinase inhibitors
|
CN102844317B
(en)
|
2010-02-18 |
2015-06-03 |
因西特公司 |
Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
|
PT3050882T
(en)
|
2010-03-10 |
2018-04-16 |
Incyte Holdings Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
AR081823A1
(en)
|
2010-04-14 |
2012-10-24 |
Incyte Corp |
FUSIONATED DERIVATIVES AS PI3Kd INHIBITORS
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
WO2011163195A1
(en)
|
2010-06-21 |
2011-12-29 |
Incyte Corporation |
Fused pyrrole derivatives as pi3k inhibitors
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
CA2822070C
(en)
|
2010-12-20 |
2019-09-17 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
PT2675451E
(en)
|
2011-02-18 |
2015-10-16 |
Incyte Corp |
Mtor/jak inhibitor combination therapy
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
ES2560611T3
(en)
|
2011-06-20 |
2016-02-22 |
Incyte Holdings Corporation |
Phenyl azetidinyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
DK2751109T3
(en)
|
2011-09-02 |
2017-01-23 |
Incyte Holdings Corp |
HETEROCYCLYLAMINES AS PI3K INHIBITORS
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
AR090548A1
(en)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
|
US9926529B2
(en)
*
|
2012-04-24 |
2018-03-27 |
International Stem Cell Corporation |
Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
|
TW201406761A
(en)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CN107383009B
(en)
|
2012-06-13 |
2020-06-09 |
因塞特控股公司 |
Substituted tricyclic compounds as FGFR inhibitors
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(en)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
Sulfonylation process using nonafluorobutanesulfonyl fluoride
|
JP6407504B2
(en)
|
2012-09-21 |
2018-10-17 |
アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. |
Method for inhibiting constitutively active phosphorylated FLT3 kinase
|
CN104918945B
(en)
|
2012-11-01 |
2018-01-05 |
因赛特公司 |
Tricyclic condensed thiophene derivant as JAK inhibitor
|
BR112015010663B1
(en)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
SUSTAINED RELEASE ORAL DOSAGE FORMS AND USE OF RUXOLITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
BR112015016282A2
(en)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanib for treatment of mutated flt3 proliferative disorders
|
TW202214254A
(en)
|
2013-03-01 |
2022-04-16 |
美商英塞特控股公司 |
USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
|
UA121532C2
(en)
|
2013-03-06 |
2020-06-10 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATES IN THE PREPARATION OF JAK INHIBITOR
|
SG11201508328PA
(en)
|
2013-04-19 |
2015-11-27 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
BR112015028501B8
(en)
|
2013-05-17 |
2023-01-24 |
Incyte Corp |
BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT
|
EP3721873A1
(en)
|
2013-08-07 |
2020-10-14 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
CA2921568A1
(en)
|
2013-08-20 |
2015-02-25 |
Incyte Corporation |
Survival benefit in patients with solid tumors with elevated c-reactive protein levels
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
LT3110409T
(en)
|
2014-02-28 |
2019-01-25 |
Incyte Corporation |
Jak1 inhibitors for the treatment of myelodysplastic syndromes
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
KR20230044320A
(en)
|
2014-04-08 |
2023-04-03 |
인사이트 코포레이션 |
Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
|
EA201692193A1
(en)
|
2014-04-30 |
2017-07-31 |
Инсайт Корпорейшн |
METHODS OF OBTAINING JAK1 INHIBITOR AND ITS NEW FORMS
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
US10065937B2
(en)
|
2014-07-31 |
2018-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
FLT3 receptor antagonists
|
MA41044A
(en)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
US9586949B2
(en)
|
2015-02-09 |
2017-03-07 |
Incyte Corporation |
Aza-heteroaryl compounds as PI3K-gamma inhibitors
|
CN107438607B
(en)
|
2015-02-20 |
2021-02-05 |
因赛特公司 |
Bicyclic heterocycles as FGFR inhibitors
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
TWI748941B
(en)
|
2015-02-27 |
2021-12-11 |
美商英塞特公司 |
Salts and processes of preparing a pi3k inhibitor
|
KR20170129802A
(en)
|
2015-03-10 |
2017-11-27 |
아두로 바이오테크, 인코포레이티드 |
Compositions and methods for activating "stimulating factors" -dependent signaling of interferon genes
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
US20160362424A1
(en)
|
2015-05-11 |
2016-12-15 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
PT3317301T
(en)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
HRP20220436T1
(en)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
PL3371190T3
(en)
|
2015-11-06 |
2022-11-07 |
Incyte Corporation |
Heterocyclic compounds as pi3k-gamma inhibitors
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
AR107293A1
(en)
|
2016-01-05 |
2018-04-18 |
Incyte Corp |
PIRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-g INHIBITORS
|
CN110218206B
(en)
*
|
2016-06-01 |
2022-03-04 |
中国海洋大学 |
Bisindolylmaleimide derivative and preparation method and application thereof
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
CA3024012A1
(en)
|
2016-11-02 |
2018-05-11 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating flt3 mutated proliferative disorders associated mutations
|
UY37695A
(en)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
|
KR20200013683A
(en)
|
2017-05-17 |
2020-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
FLT3 inhibitors for improving pain treatment by opioids
|
WO2018217766A1
(en)
|
2017-05-22 |
2018-11-29 |
Whitehead Institute For Biomedical Research |
Kcc2 expression enhancing compounds and uses thereof
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
CN107417743B
(en)
*
|
2017-06-15 |
2020-07-21 |
杭州科兴生物化工有限公司 |
Staurosporine aldehyde group substituted derivative and preparation method and application thereof
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia
|
JP7244504B2
(en)
|
2017-10-18 |
2023-03-22 |
インサイト・コーポレイション |
Fused Imidazole Derivatives Substituted with Tertiary Hydroxy Groups as PI3K-γ Inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
US11306079B2
(en)
|
2017-12-21 |
2022-04-19 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
|
EA202091830A1
(en)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR OBTAINING JAK INHIBITOR
|
MA51829A
(en)
|
2018-02-16 |
2020-12-23 |
Incyte Corp |
JAK1 PATH INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS
|
WO2019168847A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
UA128288C2
(en)
|
2018-03-08 |
2024-05-29 |
Інсайт Корпорейшн |
AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
|
EP3775284A1
(en)
|
2018-03-30 |
2021-02-17 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
MA52219A
(en)
|
2018-03-30 |
2021-02-17 |
Incyte Corp |
TREATMENT OF SUPPURED HIDRADENITIS USING JAK INHIBITORS
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
CA3099116A1
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
AU2019262195B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
US10947227B2
(en)
|
2018-05-25 |
2021-03-16 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
TW202015726A
(en)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
KR20210049090A
(en)
|
2018-07-05 |
2021-05-04 |
인사이트 코포레이션 |
Pyrazine derivatives fused as A2A/A2B inhibitors
|
WO2020028566A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
CR20210165A
(en)
|
2018-09-05 |
2021-10-01 |
Incyte Corp |
Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
KR20210118812A
(en)
|
2018-11-01 |
2021-10-01 |
사이로스 파마수티컬스, 인크. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
US11078204B2
(en)
|
2018-11-13 |
2021-08-03 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
CN113195000A
(en)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
Combination of antibody-drug conjugates and kinase inhibitors
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(en)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
EA202192260A1
(en)
|
2019-02-15 |
2021-12-17 |
Инсайт Корпорейшн |
CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND THEIR APPLICATIONS
|
TW202100520A
(en)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
CA3150975A1
(en)
|
2019-06-10 |
2020-12-17 |
Incyte Corporation |
Topical treatment of vitiligo by a jak inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
EP4013750A1
(en)
|
2019-08-14 |
2022-06-22 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
TW202115082A
(en)
|
2019-08-26 |
2021-04-16 |
美商英塞特公司 |
Triazolopyrimidines as a2a / a2b inhibitors
|
US11839619B2
(en)
|
2019-09-16 |
2023-12-12 |
The Regents Of The University Of California |
Methods for treatment of pediatric systemic mastocytosis
|
JP2022548881A
(en)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
JP2022552324A
(en)
|
2019-10-14 |
2022-12-15 |
インサイト・コーポレイション |
Bicyclic heterocycles as FGFR inhibitors
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
US11992490B2
(en)
|
2019-10-16 |
2024-05-28 |
Incyte Corporation |
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
|
WO2021076124A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
|
KR20220131900A
(en)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Derivatives of FGFR inhibitors
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
KR20230017165A
(en)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Combination therapy with AXL/MER and PD-1/PD-L1 inhibitors
|
PE20230825A1
(en)
|
2020-04-16 |
2023-05-19 |
Incyte Corp |
FUSIONED TRICYCLIC KRAS INHIBITORS
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
IL298118A
(en)
|
2020-06-02 |
2023-01-01 |
Incyte Corp |
Processes of preparing a jak1 inhibitor
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11713310B2
(en)
|
2020-07-20 |
2023-08-01 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
CN116261447A
(en)
|
2020-09-16 |
2023-06-13 |
因赛特公司 |
Topical treatment of vitiligo
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
MX2023006542A
(en)
|
2020-12-08 |
2023-08-25 |
Incyte Corp |
Jak1 pathway inhibitors for the treatment of vitiligo.
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
CN115124551B
(en)
*
|
2021-03-24 |
2024-04-30 |
奥锐特药业(天津)有限公司 |
Preparation method of high-purity midostaurin
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
US12065494B2
(en)
|
2021-04-12 |
2024-08-20 |
Incyte Corporation |
Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
|
JP2024522189A
(en)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Tricyclic Heterocycles as FGFR Inhibitors
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
TW202317565A
(en)
|
2021-07-07 |
2023-05-01 |
美商英塞特公司 |
Tricyclic compounds as inhibitors of kras
|
US20230114765A1
(en)
|
2021-07-14 |
2023-04-13 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
IL312114A
(en)
|
2021-10-14 |
2024-06-01 |
Incyte Corp |
Quinoline compounds as inhibitors of kras
|
IL312506A
(en)
|
2021-11-08 |
2024-07-01 |
Progentos Therapeutics Inc |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
MX2024006113A
(en)
|
2021-11-22 |
2024-07-29 |
Incyte Corp |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor.
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
AR128043A1
(en)
|
2021-12-22 |
2024-03-20 |
Incyte Corp |
SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR THEIR PREPARATION
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(en)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2 inhibitors and use thereof
|
TW202342023A
(en)
|
2022-03-07 |
2023-11-01 |
美商英塞特公司 |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
US20230399331A1
(en)
|
2022-06-14 |
2023-12-14 |
Incyte Corporation |
Solid forms of jak inhibitor and process of preparing the same
|
CN114853784B
(en)
*
|
2022-06-16 |
2023-09-05 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
Staurosporine compound and preparation method and application thereof
|
TW202413359A
(en)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
Bicyclic amine cdk12 inhibitors
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
US20240058343A1
(en)
|
2022-08-05 |
2024-02-22 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|